Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 26,636 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: HIV Infections, Hepatitis C
Interventions: Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 24
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Spinal Cord Injury
Interventions: Scheduled Telephone Intervention; Behavioral
Lead sponsor: Jeanne Hoffman; Other
Eligibility: 16 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Cerebrovascular Accident
Interventions: Magnesium Sulfate, Normal Saline; Drug
Lead sponsor: Jeffrey L. Saver; Other
Eligibility: 40 Years to 95 Years
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Charcot-Marie-Tooth Disease
Interventions: FLX-787-ODT (orally disintegrating tablet), Placebo ODT; Drug
Lead sponsor: Flex Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Scottsdale, Arizona • Aurora, Colorado • New Britain, Connecticut + 16 more

Conditions: Behavioral Pharmacology of Cannabinoids
Interventions: Oral Placebo, Oral THC, Oral CBD, Oral Caffeine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: IW-1701, Placebo; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Covid19
Interventions: GT0918, Standard of care, Matching placebo; Drug
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Hialeah, Florida • Lansing, Michigan • Hannibal, Missouri + 5 more

Conditions: COVID-19
Interventions: vitamin D, Placebo; Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,024 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 109
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more

Conditions: Osteoarthritis
Interventions: AGG-523; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida • Altoona, Pennsylvania

Conditions: Small Cell Lung Cancer
Interventions: Tiragolumab, Atezolizumab, Carboplatin, Etoposide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Lone Tree, Colorado • Washington D.C., District of Columbia • Fort Myers, Florida + 15 more

Conditions: Hemodialysis, Hypertension, Left Ventricular Hypertrophy
Interventions: Lisinopril, Atenolol; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Dementia With Lewy Bodies
Interventions: Irsenontrine, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 25
States / cities: Sun City, Arizona • Anaheim, California • Fountain Valley, California + 20 more

Conditions: Lateral Ankle Instability
Interventions: MBP plus arthroscopy (Group A), MBP alone (Group B); Procedure
Lead sponsor: Edna Rath; Federal
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
Interventions: MEDI-534; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 23 Months
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 30
States / cities: Conway, Arkansas • Little Rock, Arkansas • Aurora, Colorado + 25 more

Conditions: Mental Health Wellness 1
Interventions: OptimalWork, Podcast Listening; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Iron Deficiency Anemia
Interventions: Ferric Carboxymaltose (FCM), Iron Sucrose / Iron Dextran; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Olanzapine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 33
States / cities: Anaheim, California • National City, California • Orange, California + 30 more

Conditions: Dietary Habits, Health Behavior, Eating Behavior
Interventions: Behavioral Gardening Exposure, Healthy Eating and Gardening Curriculum; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 8 Years to 12 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Farmington, New Mexico • Seattle, Washington

Conditions: Anorexia Nervosa, Metabolic Syndrome
Interventions: Calorie controlled diet; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: New York, New York

Conditions: Anxiety Disorders, Mental Health
Interventions: Hypericum perforatum (St. John's wort); Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Diabetic Foot Ulcers
Interventions: Dual Layer Amniotic Membrane (DLAM). Artacent®; Biological
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Pembroke Pines, Florida + 12 more

Conditions: Breast Cancer, Osteoporosis
Interventions: zoledronic acid; Drug
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Stamford, Connecticut • Paramus, New Jersey • New York, New York

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 232
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more

Search by objective public record fields.

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

Scheduled Telephone Intervention for Individuals With Spinal Cord Injury and Their Families

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.

The Pharmacodynamics of Cannabinoid-Caffeine Combinations

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects

Vitamin D for COVID-19 Trial

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Study Evaluating AGG-523 in Subjects With Osteoarthritis

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Hypertension in Hemodialysis Patients (Aim 3)

Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

Modified Brostrӧm Procedure With and Without Possible Arthroscopy for Lateral Ankle Instability

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

Digital Intervention to Promote Medical Trainee Well-being (OptimalWork Pilot)

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Yeego! Healthy Eating & Gardening School-Based Randomized Controlled Trial

Does Metabolic Syndrome Exist in Anorexia Nervosa?

St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)

Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)